Fgf4, a member of the ®broblast growth factor family, is frequently ampli®ed in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable. This makes uncertain its involvement in tumour aetiology, although several in-vitro studies link Fgf4 overexpression to malignant transformation and metastatization of culture cells. We generated a transgenic mouse model in which the whey acidic protein (WAP) promoter directs expression of human Fgf4 to mammary tissues during late pregnancy and throughout lactation, with the purpose of studying the involvement of this growth factor in mammary tumorigenesis. Expression of the transgene was speci®cally detected in lobularalveolar cells of lactating mammary glands that, by histological analysis, displayed hyperplastic areas and a disorganized structure. This was accompanied by an increased number of red blood cells and expression, in alveolar epithelial cells, of the vascular endothelial growth factor, which is absent in wild type controls. The most striking eect caused by FGF4 overexpression was on the remodelling of mammary tissue at the end of lactation. Indeed, transgenic animals showed a delayed involution of the gland due to a dramatic reduction in the overall number of apoptotic cells, which are normally present in the organ after weaning. Nevertheless, none of the animals examined developed neoplastic lesions of the mammary gland even after several pregnancies and at old age. Our work represents the ®rst in-vivo demonstration of the anti-apoptotic and angiogenic properties of FGF4. Oncogene (2000) 19, 6007 ± 6014.
Fgf4, a member of the ®broblast growth factor family, is frequently ampli®ed in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable. This makes uncertain its involvement in tumour aetiology, although several in-vitro studies link Fgf4 overexpression to malignant transformation and metastatization of culture cells. We generated a transgenic mouse model in which the whey acidic protein (WAP) promoter directs expression of human Fgf4 to mammary tissues during late pregnancy and throughout lactation, with the purpose of studying the involvement of this growth factor in mammary tumorigenesis. Expression of the transgene was speci®cally detected in lobularalveolar cells of lactating mammary glands that, by histological analysis, displayed hyperplastic areas and a disorganized structure. This was accompanied by an increased number of red blood cells and expression, in alveolar epithelial cells, of the vascular endothelial growth factor, which is absent in wild type controls. The most striking eect caused by FGF4 overexpression was on the remodelling of mammary tissue at the end of lactation. Indeed, transgenic animals showed a delayed involution of the gland due to a dramatic reduction in the overall number of apoptotic cells, which are normally present in the organ after weaning. Nevertheless, none ofIntroduction Most of the growth and dierentiation of the mammary gland occurs during sexual maturation, and then cyclically during pregnancy and lactation. Normal as well as malignant growth is regulated by the endocrine action of steroid and peptide hormones which regulate the activity of locally acting factors, such as polypeptide growth factors (Dickson et al., 1991; Hennighausen and Robinson, 1998) . These include TGFa and EGF, both induced by oestrogens and progesterone in some breast cancer lines, IGF, and the Wnt and FGF families of growth modulators (Bates et al., 1988; Murphy et al., 1986; Baik et al., 1998; Coleman-Krnacik and Rosen, 1994; Jackson et al., 1997; Neuenschwander et al., 1996; Gavin and McMahon, 1992) . Among the growth factors we have been interested in the FGF family because alterations and/or overexpression of several of its members and their receptors have been described in human breast cancers (Penault-Llorca et al., 1995; Jaakkola et al., 1993; Payson et al., 1996) . In murine models, insertional activation of Fgf3, Fgf4 and Fgf8 by mouse mammary tumour virus (MMTV) in mammary cancers have been reported (Dickson et al., 1984; Peters et al., 1989; Shackleford et al., 1993; MacArthur et al., 1995) . In addition, transgenic mice overexpressing Fgf3 (Muller et al., 1990; Ornitz et al., 1991) and Fgf7 (Kitsberg and Leder, 1996) in the mammary gland, under the control of the MMTV promoter, develop dramatic mammary hyperplasia and tumours after a several months latency. MMTV-Fgf8 transgenic mice develop mammary gland and salivary gland neoplasia, and ovarian stromal hyperplasia (Daphna-Iken et al., 1998) . In humans, 10 ± 20% of breast tumours show gene ampli®cation of Fgf3 and Fgf4 (Theillet et al., 1989) , while their receptors, FGFR2 and FGFR1 are ampli®ed in about 12% of the cases (Adnane et al., 1991) . It has been demonstrated, in-vitro, that inappropriate expression of some FGFs or their receptors causes abnormal growth of the mammary epithelium, and human breast epithelial cells transfected with Fgf4 are converted to a tumorigenic and metastatic phenotype in a dose dependent manner (Souttou et al., 1996; McLeskey et al., 1993) . Taken together, these observations suggest that the FGF signalling pathway could play a role in the tumour progression of mammary gland.
The speci®c involvement of FGF4 in tumour development is controversial. Some human tumours appear to carry ampli®cation of both Fgf4 and Fgf3, however, no clear-cut evidence of their expression was ever found. Only recently, ampli®cation accompanied by overexpression of FGF4 has been detected in Kaposi's sarcoma (Kiuru-Kuhlefelt et al., 2000) . Although it has been hypothesized that FGF4 expression could be important only in preneoplastic lesions, its involvement in later stages of tumour progression has also been suggested (Souttou et al., 1996) , making uncertain its real role. It has been proved in mice, that inappropriate expression of this growth factor in adult tissues can lead to tumour formation (Talarico et al., 1993) . Moreover, its capacity of inducing in-vitro cell transformation through an autocrine growth mechanism has been well assessed in several models (Taylor et al., 1993; McLeskey et al., 1993; Hajitou et al., 2000) . Thus, although the oncogenic potential of Fgf4 is clearly demonstrated, further investigations are needed to clarify this issue.
In order to study the role that FGF4 might play in breast tumorigenesis, we created transgenic mice expressing the growth factor in the mammary gland under the control of the whey-acidic protein (WAP) promoter. We chose this promoter because it has been extensively used to target transgene expression to the mammary gland during mid-pregnancy and lactation with high ®delity and speci®city (Pittius et al., 1988) . WAP is a major mouse milk protein and its expression is hormonally and developmentally regulated. Being induced by prolactin, it is expressed in epithelial mammary gland cells during pregnancy and lactation and, albeit at low levels, also in virgin adult females (Robinson et al., 1995) . We demonstrated in vivo that overexpression of FGF4 could interfere with mammary gland development, induce hyperplasia, angiogenesis, and overproduction of VEGF. In addition, FGF4 dramatically inhibits cellular apoptosis after lactation, impairing tissue involution. However, its misexpression alone cannot induce mammary cells transformation.
Results

Generation of WAP-Fgf4 transgenic mice and pattern of expression in the mammary gland
We generated transgenic mice harbouring a fusion transgene consisting of 2.6 kb of the WAP gene promoter and the human Fgf4 cDNA (Figure 1a) . Founder animals were identi®ed by Southern analysis on genomic DNA obtained from the tail (Figure 1b) . We had very low transgenesis eciency, only ®ve positive animals were found out of 90 examined and two of them died at birth. The three surviving founders had a transgene copy number ranging from 10 (A112) to 100 (A81) and two of them were mosaics (A104 and A112).
Since it has been extensively proved that the WAP gene is speci®cally expressed in mammary tissues and is maximally induced by lactogenic hormones at midpregnancy and lactation, we studied expression of the transgene in the mammary gland at early stages of lactation. Expression of the transgene by Northern blotting on polyA + RNA was not detectable, we thus used RT ± PCR with oligonucleotides speci®c for human Fgf4. By RT ± PCR we found Fgf4 expression in all the transgenic animals but not in wild type controls (Figure 2) .
To determine the topographical pattern of FGF4 protein localization in the mammary gland we performed immunohistochemical analysis on sections of 3 days lactating glands from control and transgenic mice. Figure 3 compares glands derived from a homozygous A81 female (b) and a heterozygous A104 (c) with a non-transgenic control (a). Positive staining is evident in the cytoplasm of alveolar epithelial structures in both transgenic animals, while intraepithelial staining was never found in sections from non-transgenic mammary glands. The A81 female shows a weaker staining compared to A104 that displays a more dramatic phenotype. The latter line was chosen for the following studies.
Phenotype of WAP-Fgf4 transgenic mice
Transgenic females from line A81 were able to feed litters of normal size and pups with a regular body weight, and the corresponding homozygous line was established. On the contrary, only 59% of A104 females could regularly feed pups of normal size. Fourteen per cent were capable of only partial lactation and raised few pups (2 or 3) or litters of smaller size (25% reduction in body weight). The remaining 27% were unable to feed their progeny even after multiple pregnancies. Homozygous pups of line A104 appeared normal at birth. However, all showed reduced post-natal growth and the majority died before weaning. The few surviving homozygous animals were of smaller size, non-fertile and died at an early age for unknown reasons. These animals also showed an abnormal clasping of the hind feet when suspended by the tail, repetitive stroking of the nose, and sometimes exhibited epileptic seizures and died suddenly. The phenotype was irrespective of the sex of the mouse and was also observed in some heterozygous transgenic of line A112. A similar behaviour has been described in a mouse model for Huntington's disease as one of the ®rst symptoms of a progressive neurological phenotype (Mangiarini et al., 1996) . Mice carrying a null mutation in cyclin D1 and in the winged helix Mf3 gene also showed growth retardation, this abnormal behaviour and lactation defects (Fantl et al., 1995; Labosky et al., 1997) . Transgenic mice of line A112 displayed a dramatically reduced fertility and about 98% of the females that got pregnant had a null ability to care for their pups. The few females that fed the progeny would never undergo a second pregnancy and we never found homozygous pups. In addition mortality rate was very high also between heterozygous, and the percentage of positive mice within a litter was lower than expected. However, we could not associate their inability to lactate with defects in mammary gland physiology. Indeed, by histological analysis during pregnancy, the mammary gland of these females showed a phenotype similar to that displayed by A104 and droplets of secrete were visible in the cytoplasm of epithelial cells. This line was not further investigated for the present study.
Expression of WAP-Fgf4 transgene induces a mild hyperplasia and angiogenesis
Mammary glands from transgenic and control mice at day 3 of lactation, were sectioned for staining with haematoxylin and eosin. Extensive areas showing hyperplasia of epithelial cells and a disorganised structure were evident in both A81 and A104 transgenic lines (Figure 4) . At higher magni®cation, these areas displayed alveoli with a dramatic reduction of lumina space due to an increased number of epithelial cells that also exfoliate in the lumen ( Figure  3c ). The transgenic mammary gland did not have a uniform appearance and areas with normal morphology could be detected.
Another histological feature characteristic of transgenic mammary glands was the massive presence of red blood cells among the alveoli, suggestive of angiogenesis (Figure 5b ). The angiogenic properties of FGF4 have been already shown in vitro (Brustle et al., 1992) , and this is apparently mediated through an autocrine up-regulation of VEGF expression (Deroanne et al., 1997; Hajitou et al., 2000) . Indeed, by immunohistochemistry on mammary tissues at day three of lactation we demonstrated that VEGF-A is expressed speci®cally in alveolar epithelial cells of transgenic mammary gland at the same developmental time in which we observed vascular cells proliferation (Figure 5d ).
Milk proteins expression and production in transgenic females
Given the extensive lactating problems displayed by a large percentage of transgenic females we studied the content of milk proteins in the transgenic mammary glands of lactating females. By Northern analysis at dierent stages of mammary gland development and dierentiation, we could not detect signi®cant changes in the modulation of endogenous WAP expression in transgenic females compared to control littermates (Figure 6a ). Western blotting on total proteins extracted from mammary glands on day 3 of lactation evidenced a decreased amount of b-casein (26 kDa) in transgenic mammary gland (Figure 6b ). 
Mammary gland involution is retarded in transgenic mice
In order to evaluate the eect of FGF on involution of the mammary gland after forced weaning, pups were removed from their mothers at day 10 of lactation and mammary tissue was analysed during the following days. While extensive remodelling of mammary tissue occurred in controls, a markedly slower process was observed in transgenic mice. Six days after weaning control mice exhibited an evident pattern of involution and tissue remodelling in which most of the lobules and alveoli are collapsed and replaced by adipose tissue (Figure 7a ). In contrast, FGF4 transgenic mice demonstrated a considerably dierent histological pattern. At this day the gland was still ®lled with epithelial cells and little or no adipose tissue was visible, enlarged ducts ®lled with residual secretory products were still present and the gland appeared to be in an active state (Figure 7b ). After 10 days glands from transgenic females still showed large areas of epithelial cells that were no longer visible in nontransgenic controls (not shown).
Since it has been reported an involvement of FGF4 in the control of programmed cell death, we examined the spatial and temporal pattern of apoptotic nuclei in the involuting glands of control and transgenic mice by in-situ nick translation (Figure 7c,d) . As extensively described in literature, apoptotic cells were evidenced in control mammary glands as early as 1 day after weaning and the process continued up to day 10 with a peak between the 3rd and the 4th day of involution. Transgenic mammary glands exhibited a highly signi®cant reduction (as determined by the Student's ttest) in the number of apoptotic cells (450%) at all stages considered, demonstrating that the delay in gland involution is due to inhibition of apoptosis (Figure 7e ).
Tumour incidence in WAP-Fgf4 transgenic mice
In order to evaluate tumour incidence in our transgenic mice, 15 females for each transgenic line (homozygous A81 and heterozygous A104) and 15 non-transgenic controls, were bred several times (average number of pregnancies was ®ve) and observed up to 18 months of age. Ten additional females of line A104 and 10 controls were kept as virgin up to the same age. None of the animals developed mammary tumours.
Discussion
With the purpose of understanding if FGF4 can have a role in mammary tumour development, we produced transgenic mice expressing the growth factor in the mammary gland during pregnancy and lactation. The major ®nding of our study is the direct demonstration in-vivo of the antiapoptotic and angiogenic activities of FGF4. The role of FGF4 in preventing apoptosis in dental tissues has been demonstrated by pellets implant and has been directly related to the concentration of the growth factor (Vaahtokari et al., . We now demonstrate that FGF4, locally produced by mammary epithelial cells, inhibits by more than 50% the level of apoptosis at all stages of involution. The consequence is a delay of several days in tissue remodelling that, however, does not compromise further pregnancies. It is not clear at the moment if the inhibition of apoptosis re¯ects a direct role of the surviving activity of FGF4 or is mediated by antiapoptotic genes and this issue is now under investigation. It is interesting to note that endogenous FGF4 expression has been detected in the mammary gland of virgin females, but not during pregnancy and lactation (Coleman-Krnacik and Rosen, 1994). In addition, it has recently been published that the FGFR1 receptor, which also binds FGF4, is expressed in the mammary gland during ductal formation and involution, but not during late pregnancy and lactation (Chodosh et al., 2000) . Extensive tissue remodelling and high levels of apoptosis characterize both ductal development and involution. It is thus possible that FGF4 plays a role in the control of programmed cell death during these stages of mammary gland development. It will be interesting to study branching morphogenesis in our transgenic mice. Another important ®nding of our work is that FGF4 can act in vivo as an angiogenic factor leading to VEGF production and endothelial cells proliferation during lactation. The angiogenic properties of FGF4 have been tested so far only in vitro. Its proliferative activity on endothelial cells is well known and there are data indicating that this could be mediated by VEGF (Deroanne et al., 1997; Hajitou et al., 2000) . In our in-vivo model, we found an increased synthesis of VEGF speci®cally in the mammary gland of lactating transgenic mice, indicating that this could be indeed the pathway. Expression of mitogenic polypeptides able to promote endothelial cells proliferation, such as VEGF, has been documented in a lot of cultured malignant cells, and the existence of a link between angiogenesis and tumour development is now clearly ascertained. However, in our in-vivo model, stimulation of angiogenesis through VEGF is not associated with neoplastic transformation, suggesting that it could represent an early event that, creating a favourable environment, facilitates later cancer development. Recently it has been pointed out the importance of studying in vivo the events associated with activation of VEGF (Fukumura et al., 1998) and we think our mice could represent a helpful model in this respect. One additional ®nding is the development of a mild hyperplasia in transgenic epithelial mammary cells. This perturbation was not unexpected and is related to the nature of FGF4, which belongs to the ®broblast growth factors family, whose members are potent mitogens, at least for ®broblast and endothelial cells (Basilico and Moscatelli, 1992) . Mammary gland hyperplasia has been observed in other FGF transgenic mice, where it was a prelude to cancer development. Both MMTV-Fgf3 and MMTV-Fgf7 mice developed mammary tumours, albeit with dierent latency and incidence, after several months of hyperplasia (Muller et al., 1990; Kitsberg and Leder, 1996) . MMTV-Fgf8 mice showed a milder phenotype and tumour formation only after multiple pregnancies and a several months latency (Daphna-Iken et al., 1998) . Although FGF4 binds to the same receptors used by FGF8, our transgenics had several pregnancies and lived up to 24 months without developing any tumours of the mammary gland. The dierence in the phenotypes could be simply due to the use of alternative promoters (MMTV vs WAP) that lead to dierent expression levels and timing of the transgene in the mammary tissue. In fact, Fgf8 expression was detected by Northern blotting on total RNA, while we needed to use RT ± PCR in order to study transgene expression. It is interesting to note that, while transformation of NIH3T3 ®broblasts occurs with low levels of FGF4 expression (Quarto et al., 1989) , the ability of this growth factor to transform or promote progression of mammary epithelial cells has been shown to be dosedependent (Souttou et al., 1996) . Thus, dierent cell types can give dierent responses to the same growth factor and it is possible that the low expression level of Fgf4 in our transgenics is not sucient to induce complete mammary cells transformation in vivo. On the other hand, it is well possible that increasing expression of Fgf4 using a dierent promoter could impair gland functionality making impossible any analysis of the phenotype. It should also be pointed out that FGF8 can bind the same receptors stimulated by FGF4 with the exception of FGFR1(IIIc) (Ornitz et al., 1996) . It has been recently shown in vitro that FGF4 can inhibit growth of MCF7 mammary epithelial cells but not of T47D cells that do not express this receptor (Johnson et al., 1998) . In this respect it is also interesting to note that loss of FGF2, that also binds FGFR1(IIIc), in breast tumours, correlates with poor prognosis (Yiangou et al., 1997) . Thus binding of FGF4 to this receptor could counterbalance its eect on cellular apoptosis and the induction of angiogenesis, inhibiting tumour formation.
The lactating and infertility problems displayed by line A112 and, partially, by line A104 suggests that deregulation of FGF4 expression in the mammary gland can compromise the correct development of this organ. In addition, we detected defects not directly attributable to FGF4. The growth retardation of A104 homozygous pups and the abnormal behaviour of A112 heterozygous, together with the high mortality rate we observed, suggest interference with other factors. One possibility is an involvement of the hormonal balance. Although we did not perform an analysis on hormones' serum levels, it is known that FGF4 can stimulate prolactin expression and promote prolactinomas development (Shimon et al., 1996 (Shimon et al., , 1998 .
It is thus possible that the abnormal clenching behaviour and the growth defect represent`side eects' of FGF4, which is a secreted factor. However, we cannot make any conclusive statement, as this issue has not been thoroughly investigated.
Materials and methods
Plasmid and preparation of DNA for microinjection
The pWAP-Fgf4 vector (see Figure 1a) was designed to direct expression of FGF4 to the mammary gland of pregnant and lactating mice. A 2.6 Kb HindIII ± SmaI fragment, containing the WAP gene promoter was cloned into pcDKS3 (Delli Bovi et al., 1987) , containing the 1.15 Kb FGF4 cDNA linked to the Sv40 late polyadenylation region. After removal of vector sequences by restriction digestion, the microinjection fragment was puri®ed from agarose gel by electroelution and phenol : chloroform extraction, resuspended in TE buer at 1 ± 2 ng/ml and microinjected into 1-cell fertilized eggs.
Generation of transgenic mice
All the animal studies were approved by the Ethical Animal Sperimentation Committee of the National Institute for Cancer Research and carried out at the Advanced Biotechnology Centre (Genova, Italy). Single-cell embryos were harvested from the hybrid B6D2F1 strain of mice (Charles River, Italy). The WAP-FGF4 fragment was microinjected into the embryonic male pronuclei and surviving embryos were transferred to the oviducts of pseudopregnant CD-1 foster mothers (Charles River) (Hogan et al., 1994) . Genomic DNA isolated from the tail of the resulting litters was analysed by Southern blot hybridization. Brie¯y, 10 mg of genomic DNA was digested with EcoRI or SacI, resolved on a 1% agarose gel and transferred to Gene Screen Nylon membranes (NEN-Du Pont) in 106SSC. For hybridization, we used 32 P random-primed human FGF4 cDNA probe.
RNA preparation and analysis
Total RNA was isolated from tissues following the method of Chomczynski and Sacchi (1987) . RNA samples were then resolved on 1.4% agarose-formaldehyde gels, transferred to nylon membranes (Hybond N, Amersham, UK) and hybridized to 32 P-dCTP random-primed probes. Five mg of total RNA was used for WAP mRNA analysis. Mouse WAP cDNA was kindly provided by Dr J Rosen, Baylor College of Medicine, Baylor, TX, USA.
For RT ± PCR 1.25 mg of total RNA were treated with RNAse-free-DNAse and transcribed with Superscript (Gibco BRL, MD, USA) using oligoT as primer. One-tenth of the reaction was then ampli®ed with 30 cycles of PCR using oligonucleotides speci®c either for human or murine FGF4. The human speci®c oligos recognise a sequence within the same exon and, as control for genomic DNA contamination, we run reactions on duplicate samples omitting the reverse transcriptase (not shown). The murine speci®c primers instead¯ank a 400 bp intron. Sequence of the oligos is as follows: 5'-ACCTTGGTGCACTTTCTTCG the forward human primer; 5'-CTCCACTGTTGCACCAGAAA the reverse human primer; 5'-TGGTGAGCATCTTCGGAG the forward murine primer; 5'-CTGAGGGCCATGAACATAC the reverse murine primer.
Histology and analysis of apoptosis
Sections of mouse mammary glands were surgically excised and immediately placed in neutral buered formalin. Paran sections were prepared and stained with haematoxylin and eosin or with Azan trichrome. Apoptosis was identi®ed on sections by in-situ nicktranslation according to Oberhammer et al. (1993) using digoxigenin-labelled dNTPs (Boehringer Mannheim, Germany) and Klenow DNA polymerase. NBT/BCIP was used for identi®cation of apoptotic nuclei. Images from in-situ nick-translation were captured with an Olympus DP10 colour video camera attached to an Axiophot Zeiss microscope with Olympus Digital Vision software. Stained nuclei were counted in at least four ®elds per section using Adobe Photoshop software. The analysis was performed on three dierent sections of glands derived from two mice for each day of involution considered. The histogram represents the average number plus s.d.
Immunohistochemistry and Western blotting
For immunohistochemistry, sections were blocked with goat antiserum and incubated with a rabbit FGF4 antiserum (kindly provided by Prof C Basilico, NYU, New York, USA) followed by the secondary Rabbit antibody DAKO EnVision Peroxidase (Dako Corporation, CA, USA). Chromogen was the Liquid DAB substrate pack (BioGenex, CA, USA).
Anti-VEGF was purchased from Santa Cruz (CA, USA). A biotinylated goat anti-rabbit (Jackson Laboratory, ME, USA) was used as link antibody and avidin peroxidase (Jackson Laboratory) staining was revealed with Liquid DAB substrate pack.
For Western blotting the fourth mammary gland was surgically removed from 3 days lactating females and homogenized in 1 ml of RIPA buer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, 1 mM EDTA, 10 mM KCl, 20 mg/ml aprotinin). Protein concentration was determined with the BIO-RAD protein assay kit according to the manufacturer. Equal amounts of protein (100 mg) were fractionated on 12% SDS-polyacrilamide gel and transferred to nitrocellulose Hybond-C extra (Amersham, UK) following standard procedures. The blotting were then saturated in 4% BSA in T-TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween) and incubated overnight with a polyclonal rabbit antibody raised against whole milk proteins, kindly provided by Dr N Hynes, Friedrich Miescher Inst., Basel, CH. As secondary antibody we used a horseradish peroxidase-conjugated anti-rabbit IgG (Amersham). The ECL Western blotting method (Amersham) was used for detection.
